Knopp Biosciences LLC

Frontier Medicines Corp. has raised $235.5m in venture capital to date, including an $80m series C round unveiled on 22 February, although this latest financing is slightly smaller than its $88.5m se

Biopharma Financing Biopharma financings during the third quarter of 2022 totaled $18.1bn from 236 deals. The largest was a $1.39bn royalty sale by Theravance Biopharma to Royalty Pharma , which acqu

Knopp Biosciences LLC and the private equity firm Population Health Partners launched Areteia Therapeutics Inc. on July 12 with up to $350m to take Knopp’s dexpramipexole into Phase III clinical tr

Having licensed its two migraine drugs from Bristol Myers Squibb Company , Biohaven Pharmaceutical Holding Company Ltd. is tapping back into the same source with a new licensing deal for a Phase III